DAFTAR PUSTAKA

1. Kardika IBW, Herawati S, Sutirta YIWP. Preanalitik dan interpretasi glukosa darah untuk diagnosis diabetes melitus. e-jurnal Med Udayana [Internet]. 2013;20(10):1–14. Available from: http://library1.nida.ac.th/termpaper6/sd/2554/19755.pdf
2. Kemenkes RI. Lindungi Keluarga Dari Diabetes [Internet]. 2018 [cited 2021 Feb 17]. Available from: http://p2ptm.kemkes.go.id/post/lindungi-keluarga-dari-diabetes
3. Abdul M, Khan B, Hashim MJ, King JK, Govender RD, Mustafa H, et al. Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10:107–11.
4. Yosmar R, Inanta NP, Sari YO. Studi Prospektif Adverse Drug Reactions (ADRS) Obat Hipoglikemik Oral Terhadap Pasien Diabetes Mellitus Tipe 2 di Suatu Rumah Sakit, Padang. J Sains Farm Klin. 2019;5(3):169.
5. Deb T, Chakrabarty A, Ghosh A. Adverse drug reactions in Type 2 diabetes mellitus patients on oral antidiabetic drugs in a diabetes outpatient department of a tertiary care teaching hospital in the Eastern India. Int J Med Sci Public Heal. 2017;6(3):1.
6. Coleman J, Pontefract S. Adverse drug reactions. C Clin Pharmacol. 2016;16(5):481–5.
7. Poole S, Watson L, White M, Harrison S, Borthwick M, Hermingway J, et al. Oxford Handbook of Clinical Pharmacy [Internet]. 2nd ed. Wiffen P, Mitchell M, Snelling M, Stoner N, editors. Oxford: Oxford University Press; 2012. 14 p. Available from: https://books.google.co.id/books?id=_35_LGnyLsUC&printsec=frontcover&source=gbs_ge_summary_r&cad=0#v=onepage&q&f=false
8. de Vries ST, Haaijer-Ruskamp FM, de Zeeuw D, Denig P. Construct and concurrent validity of a patient-reported adverse drug event questionnaire: A cross-sectional study. Health Qual Life Outcomes. 2014;12(1):1–9.

9. Punthakee Z, Goldenberg R, Katz P. Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. Can J Diabetes [Internet]. 2018;42:S10–5. Available from: https://doi.org/10.1016/j.jcjd.2017.10.003
10. Kharroubi AT. Diabetes mellitus: The epidemic of the century. World J Diabetes. 2015;6(6):850.
11. Of D, Mellitus D. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(SUPPL.1):81–90.
12. Soelistijo SA, Lindarto D, Decroli E, Permana H, Sucipto KW, Kusnadi Y, et al. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia 2019. Perkumpulan Endokrinol Indones [Internet]. 2019;1–117. Available from: https://pbperkeni.or.id/wp-content/uploads/2020/07/Pedoman-Pengelolaan-DM-Tipe-2-Dewasa-di-Indonesia-eBook-PDF-1.pdf
13. Dipiro J, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach, Tenth Edition [Internet]. 10th Editi. McGraw-Hill Education. McGraw-Hill Education; 2017. Available from: http://accesspharmacy.mhmedical.com/content.aspx?aid=57519412
14. Amir S, Gayatri A, Estuningtyas A, Setiawati A, Muchtar A, Arif A, et al. Farmakologi dan Terapi Edisi 6. 6th Editio. Jakarta: Departemen Farmakologi dan Terapeutik FKUI; 2016.
15. Lacy C, Armstrong L, Goldman M, Lance L. Drug Information Handbook. Vol. edisi 17. 2009.
16. Rohilla A, Yadav S. Adverse Drug Reactions: An Overview. Int J Pharmacol Res [Internet]. 2013;03(01):10–2. Available from: doi:10.7439/ijpr
17. Schatz S, Weber R. Adverse drug reactions. Anaesth Intensive Care Med. 2015;21(4):212–6.
18. WHO. Module 10: Pharmacovigilance [Internet]. 2021 [cited 2021 Mar 29]. Available from: https://www.who.int/hiv/pub/10.pdf

19. BPOM RI. Modul Farmakovigilans Dasar. Jakarta; 2020.
20. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: An overview. Clin Sci. 2012;122(6):253–70.
21. Okayasu S, Kitaichi K, Hori A, Suwa T, Horikawa Y, Yamamoto M, et al. The evaluation of risk factors associated with adverse drug reactions by metformin in type 2 diabetes mellitus. Biol Pharm Bull. 2012;35(6):933–7.
22. De Jong L, Härmark L, Van Puijenbroek E. Time course, outcome and management of adverse drug reactions associated with metformin from patient's perspective: A prospective, observational cohort study in the Netherlands. Eur J Clin Pharmacol. 2016;72(5):615–22.
23. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–85.
24. Akmal M, Wadhwa R. Alpha glucosidase inhibitors [Internet]. 2021 [cited 2021 Oct 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557848/
25. Maegawa H, Tobe K, Tabuchi H, Nakamura I. Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice. Expert Opin Pharmacother [Internet]. 2016;17(15):1985–94. Available from: http://dx.doi.org/10.1080/14656566.2016.1217994
26. Utsunomiya K, Kakiuchi S, Senda M, Fujii S, Kurihara Y, Gunji R, et al. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT). J Diabetes Investig. 2020;11(4):906–16.
27. Goda M, Yamakura T, Sasaki K, Tajima T, Ueno M. Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan. Curr Med Res Opin [Internet]. 2018;34(2):319–27. Available from: http://dx.doi.org/10.1080/03007995.2017.1392293

28. Inagaki N, Nangaku M, Sakata Y, Sasaki K, Mori-Anai K, Iwasaki T, et al. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance. Adv Ther [Internet]. 2021; Available from: https://doi.org/10.1007/s12325-021-01984-4
29. Woo V, Bell A, Clement M, Noronha L, Tsoukas MA, Camacho F, et al. CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice. Diabetes, Obes Metab. 2019;21(3):691–9.
30. Ji L, Liu Y, Miao H, Xie Y, Yang M, Wang W, et al. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes, Obes Metab. 2019;21(6):1474–82.
31. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract [Internet]. 2014;103(3):373–81. Available from: http://dx.doi.org/10.1016/j.diabres.2013.12.052
32. Yoshikawa K, Tsuchiya A, Kido T, Ota T, Ikeda K, Iwakura M, et al. Long-Term Safety and Efficacy of Sitagliptin for Type 2 Diabetes Mellitus in Japan: Results of a Multicentre, Open-Label, Observational Post-Marketing Surveillance Study. Adv Ther [Internet]. 2020;37(5):2442–59. Available from: https://doi.org/10.1007/s12325-020-01293-2
33. Wang Z, Wang J, Hu J, Chen Y, Dong B, Wang Y. A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment. Life Sci [Internet]. 2021;274(16):119069. Available from: https://doi.org/10.1016/j.lfs.2021.119069
34. Yamamoto F, Unno Y, Okamura T, Ikeda R, Ochiai K, Hayashi N. Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study. Diabetes Ther [Internet]. 2020;11(1):107–17. Available from:

https://doi.org/10.1007/s13300-019-00723-x

35. Kawamori R, Kaku K, Hanafusa T, Ioriya K, Kageyama S, Hotta N. Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin. J Diabetes Investig. 2016;7(2):253–9.
36. Yanai H. Causative anti-diabetic drugs and the underlying clinical factors for hypoglycemia in patients with diabetes. World J Diabetes. 2015;6(1):30.
37. Yun JS, Ko SH. Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes. Korean J Intern Med. 2015;30(1):6–16.
38. Cryer PE. Mechanisms of Hypoglycemia-Associated Autonomic Failure in Diabetes. N Engl J Med. 2013;369(4):362–72.
39. Phillips EJ. Classifying ADRs - Does dose matter? Br J Clin Pharmacol. 2016;81(1):10–2.
40. Aronson JK, Ferner RE. The law of mass action and the pharmacological concentration-effect curve: Resolving the paradox of apparently non-dose-related adverse drug reactions. Br J Clin Pharmacol. 2016;81(1):56–61.
41. Alomar MJ. Factors affecting the development of adverse drug reactions (Review artikel) [Internet]. Saudi Pharm J. 2014 [cited 2021 Oct 23]. p. 83–4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950535/
42. Nauck M, Araki A, Hehnke U, Plat A, Clark D, Khunti K. Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. Int J Clin Pract. 2018;72(10):1–11.

LAMPIRAN 1

BUKTI SUBMIT



Gambar I.1 Bukti Submit